11 results on '"DepoCyt"'
Search Results
2. Intrathecal Chemotherapy for Central Nervous System Malignancy
- Author
-
Capozza, Michele Antonio, Mastrangelo, Stefano, Triarico, Silvia, Ruggiero, Antonio, Yaksh, Tony, editor, and Hayek, Salim, editor
- Published
- 2023
- Full Text
- View/download PDF
3. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs
- Author
-
Irene B. Vazquez Fuster, Amanda R. Taylor, Annette N. Smith, Sue H. Duran, William R. Ravis, Shanese L. Jasper, and Robert D. Arnold
- Subjects
canine ,chemotherapy ,cytarabine ,cytosar ,DepoCyt ,leukemia ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC). The use of LC has not been evaluated in dogs. Objectives To perform a LC pharmacokinetic (PK) study when administered SC in dogs. Animals Five healthy female beagles. Methods Three‐period, 3‐treatment, nonblinded, randomized, and crossover design, including a pilot study. LC was administered at 50 mg/m2 SC and FC was administered at 25 and 50 mg/m2 SC and IV. Plasma CA concentrations were measured until 240, 72, and 8 hours after SC LC, SC FC, and IV FC administration, respectively. CA plasma concentrations were quantitated by ultra‐high‐performance liquid chromatography with mass spectrometry (MS/MS) detection and concentration‐time profiles were evaluated by noncompartmental analysis. Results Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration‐time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%. The PK profiles of FC after SC and IV administration differed when compared with LC. Conclusions and Clinical Importance In healthy dogs, SC LC administration at 50 mg/m2 results in measurable plasma CA concentrations, is apparently safe and well tolerated, but does not result in prolonged cytotoxic plasma concentrations. Poor absorption of LC prevented establishment of a complete LC PK profile.
- Published
- 2020
- Full Text
- View/download PDF
4. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
- Author
-
Vazquez Fuster, Irene B., Taylor, Amanda R., Smith, Annette N., Duran, Sue H., Ravis, William R., Jasper, Shanese L., and Arnold, Robert D.
- Subjects
- *
DOGS , *PHARMACOKINETICS , *BEAGLE (Dog breed) , *BIOAVAILABILITY , *MASS spectrometry , *LIQUID chromatography - Abstract
Background: Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC). The use of LC has not been evaluated in dogs. Objectives: To perform a LC pharmacokinetic (PK) study when administered SC in dogs. Animals Five healthy female beagles. Methods: Three‐period, 3‐treatment, nonblinded, randomized, and crossover design, including a pilot study. LC was administered at 50 mg/m2 SC and FC was administered at 25 and 50 mg/m2 SC and IV. Plasma CA concentrations were measured until 240, 72, and 8 hours after SC LC, SC FC, and IV FC administration, respectively. CA plasma concentrations were quantitated by ultra‐high‐performance liquid chromatography with mass spectrometry (MS/MS) detection and concentration‐time profiles were evaluated by noncompartmental analysis. Results: Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration‐time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%. The PK profiles of FC after SC and IV administration differed when compared with LC. Conclusions and Clinical Importance: In healthy dogs, SC LC administration at 50 mg/m2 results in measurable plasma CA concentrations, is apparently safe and well tolerated, but does not result in prolonged cytotoxic plasma concentrations. Poor absorption of LC prevented establishment of a complete LC PK profile. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Multivesicular Liposome (Depofoam) in Human Diseases.
- Author
-
Salehi, Bahare, Mishra, Abhay P., Nigam, Manisha, Kobarfard, Farzad, Javed, Zeeshan, Rajabi, Sadegh, Khan, Khushbukhat, Ashfaq, Hafiz Ahsan, Ahmad, Toqeer, Pezzani, Raffaele, Ramírez-Alarcón, Karina, Martorell, Miquel, Cho, William C., Ayatollahi, Seyed Abdulmajid, and Sharifi-Rad, Javad
- Subjects
- *
POSTOPERATIVE pain , *DRUG stability , *PHARMACOLOGY , *LIPOSOMES , *PHARMACOKINETICS , *DRUG side effects , *DRUG development - Abstract
Drug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular liposomes (DepoFoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. This guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. Currently, diverse DepoFoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for postsurgical analgesia. Also, on pre-clinical trials on cancer DepoFoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. In the current work, available literature on structure, preparation and pharmacokinetics of DepoFoam are reviewed. Moreover, we investigated approved DepoFoam formulations and preclinical studies with this nanotechnology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs
- Author
-
William R. Ravis, Shanese L. Jasper, S. H. Duran, Annette N. Smith, Robert D. Arnold, Irene B. Vazquez Fuster, and Amanda R. Taylor
- Subjects
Antimetabolites, Antineoplastic ,040301 veterinary sciences ,Injections, Subcutaneous ,Encapsulated Cytarabine ,medicine.medical_treatment ,cytosar ,canine ,lymphoma ,Standard Article ,Absorption (skin) ,030204 cardiovascular system & hematology ,Pharmacology ,chemotherapy ,0403 veterinary science ,Random Allocation ,03 medical and health sciences ,Dogs ,0302 clinical medicine ,Pharmacokinetics ,medicine ,Animals ,Chemotherapy ,Liposome ,lcsh:Veterinary medicine ,Cross-Over Studies ,General Veterinary ,DepoCyt ,business.industry ,leukemia ,Cytarabine ,04 agricultural and veterinary sciences ,Crossover study ,Standard Articles ,Bioavailability ,meningoencephalomyelitis of unknown etiology ,Liposomes ,lcsh:SF600-1100 ,Administration, Intravenous ,Female ,SMALL ANIMAL ,business ,pharmacokinetics ,medicine.drug - Abstract
Background Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC). The use of LC has not been evaluated in dogs. Objectives To perform a LC pharmacokinetic (PK) study when administered SC in dogs. Animals Five healthy female beagles. Methods Three-period, 3-treatment, nonblinded, randomized, and crossover design, including a pilot study. LC was administered at 50 mg/m2 SC and FC was administered at 25 and 50 mg/m2 SC and IV. Plasma CA concentrations were measured until 240, 72, and 8 hours after SC LC, SC FC, and IV FC administration, respectively. CA plasma concentrations were quantitated by ultra-high-performance liquid chromatography with mass spectrometry (MS/MS) detection and concentration-time profiles were evaluated by noncompartmental analysis. Results Subcutaneous LC administration resulted in a maximum plasma concentration of 26.3 to 59.78 ng/mL, time to reach maximum plasma concentration of 2 hours, area under the concentration-time curve to last measurable concentration of 669.3 to 1126 h × ng/mL, and plasma bioavailability (%F) of 19.6% to 31.3%. The PK profiles of FC after SC and IV administration differed when compared with LC. Conclusions and clinical importance In healthy dogs, SC LC administration at 50 mg/m2 results in measurable plasma CA concentrations, is apparently safe and well tolerated, but does not result in prolonged cytotoxic plasma concentrations. Poor absorption of LC prevented establishment of a complete LC PK profile.
- Published
- 2020
- Full Text
- View/download PDF
7. Multivesicular Liposome (Depofoam) in Human Diseases
- Author
-
Bahare, Salehi, Abhay P, Mishra, Manisha, Nigam, Farzad, Kobarfard, Zeeshan, Javed, Sadegh, Rajabi, Khushbukhat, Khan, Hafiz Ahsan, Ashfaq, Toqeer, Ahmad, Raffaele, Pezzani, Karina, Ramírez-Alarcón, Miquel, Martorell, William C, Cho, Seyed Abdulmajid, Ayatollahi, and Javad, Sharifi-Rad
- Subjects
Depocyt ,Nanotechnology ,Drugs ,Encapsulation ,Review Article ,DepoFoam - Abstract
Drug development is a key point in the research of new therapeutic treatments for increasing maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular liposomes (DepoFoam) is a nanotechnology that allow delivery of the active constituent at a sufficient concentration during the entire treatment period. This guarantees the reduction of drug administration frequency, a very important factor in a prolonged treatment. Currently, diverse DepoFoam drugs are approved for clinical use against neurological diseases and for post-surgical pain management while other are under development for reducing surgical bleeding and for post-surgical analgesia. Also, on pre-clinical trials on cancer DepoFoam can improve bioavailability and stability of the drug molecules minimizing side effects by site-specific targeted delivery. In the current work, available literature on structure, preparation and pharmacokinetics of DepoFoam are reviewed. Moreover, we investigated approved DepoFoam formulations and preclinical studies with this nanotechnology.
- Published
- 2020
8. Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
- Author
-
Javad Sharifi-Rad, Natália Martins, Miquel Martorell, Farzad Kobarfard, Tuhin Subhra Santra, Raffaele Pezzani, Marco Redaelli, Bahare Salehi, Zeliha Selamoglu, Sadegh Rajabi, Ksenija S. Mileski, William C. Cho, Pradeep Kumar, and Instituto de Investigação e Inovação em Saúde
- Subjects
Drug ,Oncology ,Antineoplastic Agents / chemistry ,medicine.medical_specialty ,liposomal cytosine arabinoside ,medicine.medical_treatment ,media_common.quotation_subject ,Drug Compounding ,Context (language use) ,Antineoplastic Agents ,02 engineering and technology ,Review ,chemotherapy ,Biochemistry ,Targeted therapy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Animals ,Humans ,liposomal ara-C ,Cytarabine / chemistry ,Molecular Biology ,media_common ,Chemotherapy ,Cardiotoxicity ,Antineoplastic Agents / administration & dosage ,DepoCyt ,Cytarabine ,Neoplasms / drug therapy ,Cancer ,Immunotherapy ,021001 nanoscience & nanotechnology ,medicine.disease ,3. Good health ,liposomal cytarabine ,Radiation therapy ,Cytarabine / administration & dosage ,030220 oncology & carcinogenesis ,Liposomes ,cancer therapy ,Liposomes / chemistry ,0210 nano-technology - Abstract
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications. N. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the strategic project ref. UID/BIM/04293/2013 and "NORTE2020 - Programa Operacional Regional do Norte" (NORTE-01-0145-FEDER-000012). M. Martorell would like to thank the support offered by CONICYT PIA/APOYO CCTE AFB170007.
- Published
- 2019
9. From Manual Microscopy to Automated Cell Counters for First Line Screening of Body Fluids : “But not without a special body fluid mode”
- Author
-
Fleming, C.K.A. (Chérina) and Fleming, C.K.A. (Chérina)
- Abstract
Cellular analysis of body fluids, including cerebrospinal fluid and serous fluids, provides essential information in the differential diagnosis. Improper techniques and inaccurate results may lead to the under or over-diagnosis of disorders such as meningitis and peritoni
- Published
- 2016
10. Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.
- Author
-
Salehi, Bahare, Selamoglu, Zeliha, S. Mileski, Ksenija, Pezzani, Raffaele, Redaelli, Marco, C. Cho, William, Kobarfard, Farzad, Rajabi, Sadegh, Martorell, Miquel, Kumar, Pradeep, Martins, Natália, Subhra Santra, Tuhin, and Sharifi-Rad, Javad
- Subjects
- *
CANCER treatment , *ANTHRACYCLINES , *DRUG administration , *DRUG dosage , *ONCOLOGIC surgery , *DRUGS - Abstract
Cancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Cytarabine
- Abstract
No information is available on the excretion of cytarabine into breastmilk. However, the drug has a short half-life of 2 to 3 hours after intravenous administration, so it should be eliminated from milk a day after intravenous administration.[1] Very little information is available on the use of cytarabine during breastfeeding. In one case, a mother began breastfeeding her infant 3 weeks after receiving cytarabine, mitoxantrone and etoposide intravenously, with no apparent harm to her infant. After intrathecal administration of the liposomal formulation of cytarabine, drugs levels in plasma are barely detectable, and are unlikely to appear in milk in clinically relevant amounts.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.